Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multimodality Approach for Reversal of Brain Death in TBI
NCT02742857Phase 1Completed
- Sponsor
- Bioquark Inc.
- Start
- Jul 2016
- Primary completion
- Aug 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BQ-A peptide extract and mesenchymal stem cells in brain death, sponsored by Bioquark Inc. Primary endpoint: Reversal of brain death as noted in clinical examination or EEG at 15 days. Started Jul 2016; status: completed.
02
Drugs
BQ-A peptide extractmesenchymal stem cells
03
Conditions
brain death
Beyond the preview
Go deeper on NCT02742857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02742857.